The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line (Q38771103)

6 September 2017

title

The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line (English)

1 reference

6 September 2017

Raffaele Pezzani

1

1 reference

6 September 2017

Beatrice Rubin

2

1 reference

6 September 2017

Loris Bertazza

3

1 reference

6 September 2017

Marco Redaelli

4

1 reference

6 September 2017

Susi Barollo

5

1 reference

6 September 2017

Halenya Monticelli

6

1 reference

6 September 2017

Enke Baldini

7

1 reference

6 September 2017

Caterina Mian

8

1 reference

6 September 2017

Carla Mucignat

9

1 reference

6 September 2017

Carla Scaroni

10

1 reference

6 September 2017

Franco Mantero

11

1 reference

6 September 2017

Salvatore Ulisse

12

1 reference

6 September 2017

Maurizio Iacobone

13

1 reference

6 September 2017

Marco Boscaro

14

1 reference

6 September 2017

publication date

14 May 2016

1 reference

Investigational New Drugs

6 September 2017

published in

1 reference

6 September 2017

volume

34

1 reference

6 September 2017

issue

5

1 reference

6 September 2017

page(s)

531-540

1 reference

The cellular geography of aurora kinases

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Aurora kinases as anticancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Roles of Aurora kinases in mitosis and tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Spindle assembly checkpoint gene expression in childhood adrenocortical tumors (ACT): Overexpression of Aurora kinases A and B is associated with a poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Metastasis: from dissemination to organ-specific colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Adrenalectomy for solid tumor metastases: results of a multicenter European study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Operative intervention for recurrent adrenocortical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Recommendation for standardized surgical management of primary adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Human adrenocortical carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

The antiproliferative effects of ouabain and everolimus on adrenocortical tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

New naphthoquinone derivatives against glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Evolution of resistance to Aurora kinase B inhibitors in leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Functional significance of the novel H-RAS gene mutation M72I in a patient with medullary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Functions of Aurora kinase C in meiosis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Gene amplification and overexpression of Aurora-C in breast and prostate cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Aurora-kinase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

A novel HSP90 modulator with selective activity against thyroid cancers in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

Preferential amplification ofAURKA 91A (Ile31) in familial colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0358-3

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/27177645

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27177645

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-016-0358-3

1 reference

Dimensions Publication ID

6 September 2017

1002291875

0 references

1 reference